DNMR Stock Overview
Danimer Scientific, Inc., a performance polymer company, develops, produces, and provides bioplastic replacements for traditional petroleum-based plastics.
Danimer Scientific Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$2.95|
|52 Week High||US$20.40|
|52 Week Low||US$2.84|
|1 Month Change||-33.71%|
|3 Month Change||-37.50%|
|1 Year Change||-82.37%|
|3 Year Change||n/a|
|5 Year Change||n/a|
|Change since IPO||-69.43%|
Recent News & Updates
Danimer Scientific: Biodegradable Plastics Are Still Important
Summary Danimer's vision to build biodegradable plastics has continued even as its commons have collapsed to new lows. Whilst partnerships with consumer packaged goods companies have helped the company realize healthy revenue, the recent revenue trajectory has been negative. The company is burning through cash at a high pace, and its overall liquidity position looks increasingly difficult. Danimer Scientific (DNMR) is pioneering the creation of sustainable and more natural ways to make plastic products. The Bainbridge, Georgia-based company produces biopolymers that have helped create plastic products that are biodegradable and compostable. This mission drove a significant level of investor enthusiasm when the company was listed on the NYSE via a blank check firm back in the winter of 2020. The next few months after this would come to be characterized by excessive animal spirits and unfettered expectations on the seemingly large total addressable market being pursued by Danimer. Indeed, the company had guided for revenue to reach $193 million in the current fiscal 2022, rising further to reach $513 million in fiscal 2025 with a 5-year compound annual growth rate of around 59% from fiscal 2020. Growth was meant to be bountiful and would be driven by the greater permeability of ESG in corporate America. This would drive firms to pay more attention to the great call of sustainability being demanded by their customers and would see many corporate sustainability commitments dealing with packaging enacted. Numerous sustainability-minded consumer packaged goods companies have looked at packaging improvements as a key way to meet these internal goals. Danimer has signed numerous partnerships with a broad range of companies including Nestle (NSRGY) and Bacardi on the back of this. Most recently, this will see the company partner with Mars Wrigley for two years to create biodegradable candy wrappers. Mars Wrigley, like many of its CPG peers, is looking to make 100% of its packaging reusable, recyclable or compostable by 2025. Hence, against a positive macro context, the retracement of Danimer's common shares has become an incredibly tragic outcome. It mirrors the fate of many growth stocks that went public on the hype of the now-dead SPAC boom. Their futures have seemingly been dashed by the total collapse of the stock market over the last year as a hawkish Fed raises rates to historic highs to try to fight of a multi-layered and relentless bout of inflation. The ensuing drawdown of liquidity has wreaked havoc on capital market-funded growth plans and has meant that Danimer, in just a few years after going public, has slid into relative obscurity and declined to levels that would seem alien to its initial investors back in the winter of 2020. Revenue Growth Goes Negative Even Against Demand For Biodegradable Plastics The company last reported earnings for its fiscal 2022 second quarter, which saw revenue come in at $12.7 million. This was a decrease of 12.2% from the year-ago quarter and a $2.66 million miss on consensus estimates. The company attributed the decline to lower PLA sales and lower R&D revenue. This was partially offset by an increase in Nodax PHA sales. Nodax is Danimer's biodegradable and sustainable plastic that is made through a natural fermentation process using plant oils, including soy and canola as feedstock. PHA-based resin sales were up 84.5% to $7.7 million, representing 61% of total revenues compared to 29% in the year-ago quarter. Gross profit was negative at $2.2 million versus a profit of $2 million in the comparable year-ago period, with the decline in higher margin R&D revenues contributing to this inversion. The quarter was not great. Cash burn from operations came in at $19.8 million as net loss reached $30.4 million. With capital expenditure of $50 million during the quarter, Danimer's cash and equivalents positions fell to $140 million from $210 million in the first quarter of fiscal 2022. As the company expects to spend a further $66 million to $76 million this year, its cash position stands to fall to a record public low against what remains anemic revenue growth and negative gross profits. Post-period end, Danimer embarked on a $100 million mixed securities offering to expand out a runway that looked set to end by the first half of fiscal 2023. Whilst it will significantly dilute current shareholders as it amounts to just over one-third of Danimer's current $293 million market cap, it is a necessary act by management to keep Danimer as a going concern. Biodegradable Plastics Are Still Important With only around 10% of plastics being recycled, Danimer's management still thinks they are chasing a large TAM. However, bears have argued that biodegradable plastics which aim to solve the single-use plastic dilemma are not the right solution and represent a more expensive over-engineering of the problem.
Danimer Scientific stock slides on $100M securities offering
Danimer Scientific (NYSE:DNMR) shares have plunged around 12% on Friday after the performance polymer company registered for a $100M mixed securities offering. Late Thursday, the company filed to sell common stock, preferred stock, debt securities, guarantees of debt securities or warrants up to an aggregate amount of $100M. The filing does not necessarily indicate that a sale has begun, or will occur in the future. Terms of the offering, including price, is yet to be determined.
These Analysts Think Danimer Scientific, Inc.'s (NYSE:DNMR) Sales Are Under Threat
The analysts covering Danimer Scientific, Inc. ( NYSE:DNMR ) delivered a dose of negativity to shareholders today, by...
|DNMR||US Chemicals||US Market|
Return vs Industry: DNMR underperformed the US Chemicals industry which returned -13.5% over the past year.
Return vs Market: DNMR underperformed the US Market which returned -21.5% over the past year.
|DNMR Average Weekly Movement||13.7%|
|Chemicals Industry Average Movement||6.4%|
|Market Average Movement||6.9%|
|10% most volatile stocks in US Market||15.6%|
|10% least volatile stocks in US Market||2.8%|
Stable Share Price: DNMR is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 14% a week.
Volatility Over Time: DNMR's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
Danimer Scientific, Inc., a performance polymer company, develops, produces, and provides bioplastic replacements for traditional petroleum-based plastics. It produces polyhydroxyalkanoate, a biodegradable plastic feedstock alternative used in a range of plastic applications, including films, straws, food containers, and other things under the Nodax brand name; polylactic acid-based resins for coating disposable paper cups; and other biopolymers. The company offers its products for biopolymers, including additives, aqueous coatings, fibers, filaments, films, thermoforming, and injection-molded articles.
Danimer Scientific Fundamentals Summary
|DNMR fundamental statistics|
Is DNMR overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|DNMR income statement (TTM)|
|Cost of Revenue||US$62.12m|
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
|Earnings per share (EPS)||-0.61|
|Net Profit Margin||-104.97%|
How did DNMR perform over the long term?See historical performance and comparison
Is DNMR undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score 0/6
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Key Valuation Metric
Which metric is best to use when looking at relative valuation for DNMR?
Other financial metrics that can be useful for relative valuation.
|What is DNMR's n/a Ratio?|
Price to Sales Ratio vs Peers
How does DNMR's PS Ratio compare to its peers?
|DNMR PS Ratio vs Peers|
|Company||PS||Estimated Growth||Market Cap|
ASPN Aspen Aerogels
RYAM Rayonier Advanced Materials
DNMR Danimer Scientific
Price-To-Sales vs Peers: DNMR is expensive based on its Price-To-Sales Ratio (5.1x) compared to the peer average (0.9x).
Price to Earnings Ratio vs Industry
How does DNMR's PE Ratio compare vs other companies in the US Chemicals Industry?
Price-To-Sales vs Industry: DNMR is expensive based on its Price-To-Sales Ratio (5.1x) compared to the US Chemicals industry average (1x)
Price to Sales Ratio vs Fair Ratio
What is DNMR's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
|Current PS Ratio||5.1x|
|Fair PS Ratio||2.8x|
Price-To-Sales vs Fair Ratio: DNMR is expensive based on its Price-To-Sales Ratio (5.1x) compared to the estimated Fair Price-To-Sales Ratio (2.8x).
Share Price vs Fair Value
What is the Fair Price of DNMR when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate DNMR's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate DNMR's fair value for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.
Discover undervalued companies
How is Danimer Scientific forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?
Future Growth Score2/6
Future Growth Score 2/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: DNMR is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: DNMR is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: DNMR is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: DNMR's revenue (53.5% per year) is forecast to grow faster than the US market (7.6% per year).
High Growth Revenue: DNMR's revenue (53.5% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if DNMR's Return on Equity is forecast to be high in 3 years time
Discover growth companies
How has Danimer Scientific performed over the past 5 years?
Past Performance Score0/6
Past Performance Score 0/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: DNMR is currently unprofitable.
Growing Profit Margin: DNMR is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: DNMR is unprofitable, and losses have increased over the past 5 years at a rate of 47.8% per year.
Accelerating Growth: Unable to compare DNMR's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: DNMR is unprofitable, making it difficult to compare its past year earnings growth to the Chemicals industry (21.1%).
Return on Equity
High ROE: DNMR has a negative Return on Equity (-13.02%), as it is currently unprofitable.
Discover strong past performing companies
How is Danimer Scientific's financial position?
Financial Health Score2/6
Financial Health Score 2/6
Short Term Liabilities
Long Term Liabilities
Stable Cash Runway
Forecast Cash Runway
Financial Position Analysis
Short Term Liabilities: DNMR's short term assets ($202.0M) exceed its short term liabilities ($30.6M).
Long Term Liabilities: DNMR's short term assets ($202.0M) do not cover its long term liabilities ($288.3M).
Debt to Equity History and Analysis
Debt Level: DNMR's net debt to equity ratio (26.3%) is considered satisfactory.
Reducing Debt: Insufficient data to determine if DNMR's debt to equity ratio has reduced over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: DNMR has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: DNMR has less than a year of cash runway if free cash flow continues to reduce at historical rates of 76.7% each year
Discover healthy companies
What is Danimer Scientific current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Cash Flow Coverage
Dividend Yield vs Market
|Danimer Scientific Dividend Yield vs Market|
|Company (Danimer Scientific)||n/a|
|Market Bottom 25% (US)||1.7%|
|Market Top 25% (US)||4.7%|
|Industry Average (Chemicals)||2.4%|
|Analyst forecast in 3 Years (Danimer Scientific)||n/a|
Notable Dividend: Unable to evaluate DNMR's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate DNMR's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if DNMR's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if DNMR's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as DNMR has not reported any payouts.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Stephen Croskrey (61 yo)
Mr. Stephen E. Croskrey has been the Chief Executive Officer and Director of Danimer Scientific, Inc. since February 2016 and serves as its Chairman of the Board since December 2020. Mr. Croskrey was Legac...
CEO Compensation Analysis
|Stephen Croskrey's Compensation vs Danimer Scientific Earnings|
|Date||Total Comp.||Salary||Company Earnings|
|Jun 30 2022||n/a||n/a|
|Mar 31 2022||n/a||n/a|
|Dec 31 2021||US$72m||US$875k|
|Sep 30 2021||n/a||n/a|
|Jun 30 2021||n/a||n/a|
|Mar 31 2021||n/a||n/a|
|Dec 31 2020||US$29m||US$424k|
|Sep 30 2020||n/a||n/a|
|Jun 30 2020||n/a||n/a|
|Mar 31 2020||n/a||n/a|
|Dec 31 2019||US$6m||US$394k|
Compensation vs Market: Stephen's total compensation ($USD71.86M) is above average for companies of similar size in the US market ($USD1.72M).
Compensation vs Earnings: Stephen's compensation has increased whilst the company is unprofitable.
Experienced Management: DNMR's management team is not considered experienced ( 1.7 years average tenure), which suggests a new team.
Experienced Board: DNMR's board of directors are considered experienced (3.3 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: DNMR insiders have only sold shares in the past 3 months.
Recent Insider Transactions
|19 Aug 22||SellUS$872,893||Stuart Pratt||Individual||175,327||US$5.25|
|Owner Type||Number of Shares||Ownership Percentage|
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 3.5%.
|Ownership||Name||Shares||Current Value||Change %||Portfolio %|
Danimer Scientific, Inc.'s employee growth, exchange listings and data sources
- Name: Danimer Scientific, Inc.
- Ticker: DNMR
- Exchange: NYSE
- Founded: 2004
- Industry: Specialty Chemicals
- Sector: Materials
- Implied Market Cap: US$298.469m
- Shares outstanding: 101.18m
- Website: https://www.danimerscientific.com
Number of Employees
- Danimer Scientific, Inc.
- 140 Industrial Boulevard
- United States
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|DNMR *||BMV (Bolsa Mexicana de Valores)||Yes||New Common Stock||MX||MXN||May 2020|
|DNMR||NYSE (New York Stock Exchange)||Yes||New Common Stock||US||USD||May 2020|
|6CU||MUN (Boerse Muenchen)||Yes||New Common Stock||DE||EUR||May 2020|
|6CU||DB (Deutsche Boerse AG)||Yes||New Common Stock||DE||EUR||May 2020|
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/09/30 00:00|
|End of Day Share Price||2022/09/30 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.